1,013 results on '"Kupelian, Patrick A."'
Search Results
2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
- Author
-
Kishan, Amar U, Steigler, Alison, Denham, James W, Zapatero, Almudena, Guerrero, Araceli, Joseph, David, Maldonado, Xavier, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Tosoian, Jeffrey J, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Jiang, Tommy, Ma, T Martin, Xiang, Michael, Philipson, Rebecca, Chang, Albert, Kupelian, Patrick A, Rettig, Matthew B, Feng, Felix Y, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Boutros, Paul C, Horwitz, Eric M, Tendulkar, Rahul D, Spratt, Daniel E, and Romero, Tahmineh
- Subjects
Cancer ,Clinical Research ,Prostate Cancer ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Androgen Antagonists ,Androgens ,Brachytherapy ,Data Analysis ,Humans ,Male ,Middle Aged ,Prostatic Neoplasms ,Retrospective Studies ,Oncology and Carcinogenesis ,Public Health and Health Services - Abstract
ImportanceRadiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT is uncertain.ObjectiveTo determine the specific ADT duration threshold that provides a distant metastasis-free survival (DMFS) benefit in patients with high-risk prostate cancer receiving external beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, settings, and participantsThis was a cohort study of 3 cohorts assembled from a multicenter retrospective study (2000-2013); a post hoc analysis of the Randomized Androgen Deprivation and Radiotherapy 03/04 (RADAR; 2003-2007) randomized clinical trial (RCT); and a cross-trial comparison of the RADAR vs the Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy; DART) 01/05 RCT (2005-2010). In all, the study analyzed 1827 patients treated with EBRT and 1108 patients treated with EBRT+BT from the retrospective cohort; 181 treated with EBRT and 203 with EBRT+BT from RADAR; and 91 patients treated with EBRT from DART. The study was conducted from October 15, 2020, to July 1, 2021, and the data analyses, from January 5 to June 15, 2021.ExposuresHigh-dose EBRT or EBRT+BT for an ADT duration determined by patient-physician choice (retrospective) or by randomization (RCTs).Main outcomes and measuresThe primary outcome was DMFS; secondary outcome was overall survival (OS). Natural cubic spline analysis identified minimum thresholds (months).ResultsThis cohort study of 3 studies totaling 3410 men (mean age [SD], 68 [62-74] years; race and ethnicity not collected) with high-risk prostate cancer found a significant interaction between the treatment type (EBRT vs EBRT+BT) and ADT duration (binned to
- Published
- 2022
3. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
- Author
-
Ma, Ting Martin, Gafita, Andrei, Shabsovich, David, Juarez, Jesus, Grogan, Tristan R, Thin, Pan, Armstrong, Wesley, Sonni, Ida, Nguyen, Kathleen, Lok, Vincent, Reiter, Robert E, Rettig, Matthew B, Steinberg, Michael L, Kupelian, Patrick A, Yang, David D, Muralidhar, Vinayak, Chu, Carissa, Feng, Felix, Savjani, Ricky, Deng, Jie, Parikh, Neil R, Nickols, Nicholas G, Elashoff, David, Czernin, Johannes, Calais, Jeremie, and Kishan, Amar U
- Subjects
Prostate ,Humans ,Prostatic Neoplasms ,Nomograms ,Prospective Studies ,Male ,Clinical Trials as Topic ,Positron Emission Tomography Computed Tomography ,Conventional imaging ,Gleason grade ,Nomogram ,Overall upstaging ,Percent positive core ,Positron emission tomography/computed tomography ,Prostate cancer ,Prostate-specific membrane antigen ,Staging ,Biomedical Imaging ,Prostate Cancer ,Urologic Diseases ,Aging ,Clinical Research ,Cancer ,Prevention ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis - Abstract
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data from two prospective trials (NCT03368547 and NCT04050215), we explored predictors of overall upstaging (nodal and metastatic) by PSMA PET/CT among patients with cN0M0 National Comprehensive Cancer Network high-risk PCa on conventional imaging (n = 213). Overall, 21.1%, 8.9%, and 23.9% of patients experienced nodal, metastatic, and overall upstaging, respectively, without histologic confirmation. On multivariable analysis, Gleason grade group (GG) and percent positive core (PPC) on systematic biopsy significantly predict overall upstaging (odds ratio [OR] 2.15, 95% confidence interval [CI] 1.33-3.45; p = 0.002; and OR 1.03, 95% CI 1.01-1.04; p
- Published
- 2022
4. Image-Guided Radiotherapy in Lung Cancer
- Author
-
Weng, Julius, Kupelian, Patrick, Lee, Percy, and Jeremić, Branislav, editor
- Published
- 2023
- Full Text
- View/download PDF
5. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
- Author
-
Xiang, Michael, Martin, Ting, Savjani, Ricky, Pollom, Erqi L, Karnes, R Jeffrey, Grogan, Tristan, Wong, Jessica K, Motterle, Giovanni, Tosoian, Jeffrey J, Trock, Bruce J, Klein, Eric A, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Levin-Epstein, Rebecca, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Huland, Hartwig, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Alam, Ridwan, Schwen, Zeyad, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Chong, Natalie, Kupelian, Patrick A, Rettig, Matthew B, Zaorsky, Nicholas G, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, Tilki, Derya, Czernin, Johannes, Gafita, Andrei, Romero, Tahmineh, Calais, Jeremie, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Prostate Cancer ,Cancer ,Clinical Research ,Urologic Diseases ,Aging ,Prevention ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Antigens ,Surface ,Biomarkers ,Tumor ,Clinical Decision Rules ,Follow-Up Studies ,Glutamate Carboxypeptidase II ,Humans ,Male ,Middle Aged ,Neoplasm Staging ,Nomograms ,Positron Emission Tomography Computed Tomography ,Prognosis ,Prostatic Neoplasms ,Retrospective Studies ,Risk Assessment ,SEER Program ,Survival Analysis ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceProstate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear.ObjectivesTo evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocalized upstaging on PSMA PET/CT and to compare its performance with existing risk-stratification tools.Design, setting, and participantsThis cohort study included patients diagnosed with high-risk or very high-risk prostate cancer (ie, prostate-specific antigen [PSA] level >20 ng/mL, Gleason score 8-10, and/or clinical stage T3-T4, without evidence of nodal or metastatic disease by conventional workup) from April 1995 to August 2018. This multinational study was conducted at 15 centers. Data were analyzed from December 2020 to March 2021.ExposuresCurative-intent radical prostatectomy (RP), external beam radiotherapy (EBRT), or EBRT plus brachytherapy (BT), with or without androgen deprivation therapy.Main outcomes and measuresPSMA upstage probability was calculated from a nomogram using the biopsy Gleason score, percentage positive systematic biopsy cores, clinical T category, and PSA level. Biochemical recurrence (BCR), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS) were analyzed using Fine-Gray and Cox regressions. Model performance was quantified with the concordance (C) index.ResultsOf 5275 patients, the median (IQR) age was 66 (60-72) years; 2883 (55%) were treated with RP, 1669 (32%) with EBRT, and 723 (14%) with EBRT plus BT; median (IQR) PSA level was 10.5 (5.9-23.2) ng/mL; 3987 (76%) had Gleason grade 8 to 10 disease; and 750 (14%) had stage T3 to T4 disease. Median (IQR) follow-up was 5.1 (3.1-7.9) years; 1221 (23%) were followed up for at least 8 years. Overall, 1895 (36%) had BCR, 851 (16%) developed DM, and 242 (5%) died of prostate cancer. PSMA upstage probability was significantly prognostic of all clinical end points, with 8-year C indices of 0.63 (95% CI, 0.61-0.65) for BCR, 0.69 (95% CI, 0.66-0.71) for DM, 0.71 (95% CI, 0.67-0.75) for PCSM, and 0.60 (95% CI, 0.57-0.62) for PCSM (P
- Published
- 2021
6. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
- Author
-
Philipson, Rebecca G, Romero, Tahmineh, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Braccioforte, Michelle, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Valle, Luca, Chong, Natalie, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Klein, Eric A, Tosoian, Jeffrey J, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Kupelian, Patrick A, Rettig, Matthew B, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Urologic Diseases ,Prostate Cancer ,Cancer ,Clinical Research ,Aging ,Brachytherapy ,Humans ,Male ,Neoplasm Grading ,Prostate ,Prostatic Neoplasms ,Salvage Therapy ,Biochemical recurrence ,Brachytherapy boost ,EBRT ,External beam radiation therapy ,High-risk prostate cancer ,Prostate cancer ,Radiorecurrence ,Recurrent prostate cancer ,Urology & Nephrology ,Clinical sciences - Abstract
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p
- Published
- 2021
7. The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells
- Author
-
Nickols, Nicholas G, Ganapathy, Ekambaram, Nguyen, Christine, Kane, Nathanael, Lin, Lin, Diaz-Perez, Silvia, Nazarian, Ramin, Mathis, Colleen, Felix, Care, Basehart, Vince, Zomorodian, Nazy, Kwak, Jae, Kishan, Amar U, King, Christopher R, Kupelian, Patrick A, Rettig, Matthew B, Steinberg, Michael L, Cao, Minsong, Knudsen, Beatrice S, Chu, Fang-I, Romero, Tahmineh, Elashoff, David, Reiter, Robert E, and Schaue, Dörthe
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Vaccine Related ,Prostate Cancer ,Cancer ,Clinical Trials and Supportive Activities ,Urologic Diseases ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Humans ,Immunotherapy ,Injections ,Intralymphatic ,Male ,Middle Aged ,Myeloid Cells ,Neoadjuvant Therapy ,Neoplasm Grading ,Prostate ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Radiosurgery ,Urology & Nephrology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundHundreds of ongoing clinical trials combine radiation therapy, mostly delivered as stereotactic body radiotherapy (SBRT), with immune checkpoint blockade. However, our understanding of the effect of radiotherapy on the intratumoral immune balance is inadequate, hindering the optimal design of trials that combine radiation therapy with immunotherapy. Our objective was to characterize the intratumoral immune balance of the malignant prostate after SBRT in patients.MethodsSixteen patients with high-risk, non-metastatic prostate cancer at comparable Gleason Grade disease underwent radical prostatectomy with (n = 9) or without (n = 7) neoadjuvant SBRT delivered in three fractions of 8 Gy over 5 days completed 2 weeks before surgery. Freshly resected prostate specimens were processed to obtain single-cell suspensions, and immune-phenotyped for major lymphoid and myeloid cell subsets by staining with two separate 14-antibody panels and multicolor flow cytometry analysis.ResultsMalignant prostates 2 weeks after SBRT had an immune infiltrate dominated by myeloid cells, whereas malignant prostates without preoperative treatment were more lymphoid-biased (myeloid CD45+ cells 48.4 ± 19.7% vs. 25.4 ± 7.0%; adjusted p-value = 0.11; and CD45+ lymphocytes 51.6 ± 19.7% vs. 74.5 ± 7.0%; p = 0.11; CD3+ T cells 35.2 ± 23.8% vs. 60.9 ± 9.7%; p = 0.12; mean ± SD).ConclusionSBRT drives a significant lymphoid to myeloid shift in the prostate-tumor immune infiltrate. This may be of interest when combining SBRT with immunotherapies, particularly in prostate cancer.
- Published
- 2021
8. Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control
- Author
-
Levin-Epstein, Rebecca G, Jiang, Naomi Y, Wang, Xiaoyan, Upadhyaya, Shrinivasa K, Collins, Sean P, Suy, Simeng, Aghdam, Nima, Mantz, Constantine, Katz, Alan J, Miszczyk, Leszek, Napieralska, Aleksandra, Namysl-Kaletka, Agnieszka, Prionas, Nicholas, Bagshaw, Hilary, Buyyounouski, Mark K, Cao, Minsong, Agazaryan, Nzhde, Dang, Audrey, Yuan, Ye, Kupelian, Patrick A, Zaorsky, Nicholas G, Spratt, Daniel E, Mohamad, Osama, Feng, Felix Y, Mahal, Brandon A, Boutros, Paul C, Kishan, Arun U, Juarez, Jesus, Shabsovich, David, Jiang, Tommy, Kahlon, Sartajdeep, Patel, Ankur, Patel, Jay, Nickols, Nicholas G, Steinberg, Michael L, Fuller, Donald B, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Radiation Oncology ,Aging ,Urologic Diseases ,Prostate Cancer ,6.5 Radiotherapy and other non-invasive therapies ,Humans ,Kinetics ,Male ,Prospective Studies ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Radiosurgery ,Prostate cancer ,Stereotactic body radiation therapy ,SBRT ,Dose-escalation ,Dose-response ,Biochemical control ,Dose–response ,Other Physical Sciences ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis ,Medical and biological physics - Abstract
Background and purposeThe optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose-response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR) among 4 SBRT dose regimens.Materials and methodsIn 1908 men with low-risk (50.0%), favorable intermediate-risk (30.9%), and unfavorable intermediate-risk (19.1%) prostate cancer treated with prostate SBRT across 8 institutions from 2003 to 2018, we examined 4 regimens (35 Gy/5 fractions [35/5, n = 265, 13.4%], 36.25 Gy/5 fractions [36.25/5, n = 711, 37.3%], 40 Gy/5 fractions [40/5, n = 684, 35.8%], and 38 Gy/4 fractions [38/4, n = 257, 13.5%]). Between dose groups, we compared PSA decay slope, nadir PSA (nPSA), achievement of nPSA ≤0.2 and ≤0.5 ng/mL, and BCR-free survival (BCRFS).ResultsMedian follow-up was 72.3 months. Median nPSA was 0.01 ng/mL for 38/4, and 0.17-0.20 ng/mL for 5-fraction regimens (p
- Published
- 2021
9. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer
- Author
-
Parikh, Neil R, Kishan, Amar U, Kane, Nathanael, Diaz-Perez, Silvia, Ganapathy, Ekambaram, Nazarian, Ramin, Felix, Carol, Mathis, Colleen, Bradley, Margaret, Sachdeva, Ankush, Wyatt, Bashir, Basehart, Vince, Zomorodian, Nazy, Lin, Lin, King, Christopher R, Kupelian, Patrick A, Rettig, Matthew B, Steinberg, Michael L, Cao, Minsong, Knudsen, Beatrice S, Elashoff, David, Schaue, Dorthe, Reiter, Robert E, and Nickols, Nicholas G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Urologic Diseases ,Patient Safety ,Clinical Research ,Clinical Trials and Supportive Activities ,Prostate Cancer ,Aging ,Cancer ,Management of diseases and conditions ,7.1 Individual care needs ,Feasibility Studies ,Follow-Up Studies ,Humans ,Male ,Neoadjuvant Therapy ,Prostate ,Prostatectomy ,Prostatic Neoplasms ,Quality of Life ,Radiosurgery ,Seminal Vesicles ,Urinary Incontinence ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeThis study aimed to evaluate the feasibility and safety of prostate stereotactic body radiation therapy (SBRT) neoadjuvant to radical prostatectomy (RP) in a phase 1 trial. The primary endpoint was treatment completion rate without severe acute surgical complications. Secondary endpoints included patient-reported quality of life and physician-reported toxicities.Methods and materialsPatients with nonmetastatic high-risk or locally advanced prostate cancer received 24 Gy in 3 fractions to the prostate and seminal vesicles over 5 days, completed 2 weeks before RP. Patients with pN1 disease were treated after multidisciplinary discussion and shared decision making. Patient-reported quality of life (International Prostate Symptom Score and Expanded Prostate Cancer Index Composite 26-item version questionnaires) and physician-reported toxicity (Common Terminology Criteria for Adverse Events, version 4.03) were assessed before SBRT, immediately before surgery, and at 3-month intervals for 1 year.ResultsTwelve patients were enrolled, and 11 completed treatment (1 patient had advanced disease on prostate-specific membrane antigen positron emission tomography after enrollment but before treatment). There were no significant surgical complications. After RP, 2 patients underwent additional radiation therapy to nodes with androgen suppression for pN1 disease. Median follow-up after completion of treatment was 20.1 months, with 9 of 11 patients having a follow-up period of >12 months. Two patients had biochemical recurrence (prostate-specific antigen ≥0.05) within the first 12 months, with an additional 2 patients found to have biochemical recurrence after the 12-month period. The highest Common Terminology Criteria for Adverse Events genitourinary grades were 0, 1, 2, and 3 (n = 1, 4, 4, and 2, respectively), and the highest gastrointestinal grades were 0, 1, and 2 (n = 9, 1, and 1, respectively). At 12 months, incontinence was the only grade ≥2 toxicity. One and 2 of 9 patients had grade 2 and 3 incontinence, respectively. On the Expanded Prostate Cancer Index Composite (26-item version), the mean/median changes in scores from baseline to 12 months were -32.8/-31.1 for urinary incontinence, -1.6/-6.2 for urinary irritative/obstructive, -2.1/0 for bowel, -34.4/-37.5 for sexual function, and -10.6/-2.5 for hormonal. The mean/median change in International Prostate Symptom Score from baseline to 12 months was 0.5/0.5.ConclusionsRP after neoadjuvant SBRT appears to be feasible and safe at the dose tested. The severity of urinary incontinence may be higher than RP alone.
- Published
- 2020
10. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials
- Author
-
Kishan, Amar U, Chu, Fang-I, King, Christopher R, Seiferheld, Wendy, Spratt, Daniel E, Tran, Phuoc, Wang, Xiaoyan, Pugh, Stephanie E, Sandler, Kiri A, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nickols, Nicholas G, Rettig, Matthew, Drakaki, Alexandra, Liu, Sandy T, Reiter, Robert E, Chang, Albert J, Feng, Felix Y, Sajed, Dipti, Nguyen, Paul L, Kupelian, Patrick A, Steinberg, Michael L, Boutros, Paul C, Elashoff, David, Collette, Laurence, and Sandler, Howard M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prostate Cancer ,Radiation Oncology ,Cancer ,Aging ,Clinical Trials and Supportive Activities ,Urologic Diseases ,Clinical Research ,Humans ,Male ,Neoplasm Grading ,Prostatic Neoplasms ,Randomized Controlled Trials as Topic ,Treatment Failure ,Local failure ,Radiotherapy ,High grade ,Urology & Nephrology ,Clinical sciences - Abstract
BackgroundThe importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.ObjectiveTo evaluate the clinical implications of LF after definitive RT.Design, setting, and participantsIndividual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials.Outcome measurements and statistical analysisMultivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints.Results and limitationsMedian follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37-2.10]), PCSS (3.10 [95% CI 2.33-4.12]), and DMFS (HR 1.92 [95% CI 1.54-2.39]), p
- Published
- 2020
11. Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer
- Author
-
Levin-Epstein, Rebecca, Qiao-Guan, George, Juarez, Jesus E, Shen, Zhouhuizi, Steinberg, Michael L, Ruan, Dan, Valle, Luca, Nickols, Nicholas G, Kupelian, Patrick A, King, Christopher R, Cao, Minsong, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Bioengineering ,Prostate Cancer ,Clinical Research ,Urologic Diseases ,Cancer ,prostate cancer ,stereotactic body radiation therapy ,SBRT ,prostate motion ,planning target volume ,margins ,image-guidance ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiotherapy (SBRT) of prostate cancer based on inter- and intra-fractional prostate motion determined from daily image guidance. Methods and Materials: Two hundred and five patients who were enrolled on two prospective studies of SBRT (8 Gy × 5 fractions) for localized prostate cancer treated at a single institution between 2012 and 2017 had complete inter- and intra-fractional shift data available. All patients had scheduled kilovoltage planar imaging during SBRT with rigid registration to intraprostatic fiducials prior to each of four half-arcs delivered per fraction, as well as cone beam CT verification of anatomy prior to each fraction. Inter- and intra- fractional shift data were obtained to estimate the required PTV margins based on the classic van Herk formula. Inter- and intra-fractional motion were compared between patients with and without severe toxicities using the independent two-sample Wilcoxon test. Results: The margins required to account for inter-fractional motion were estimated to be 0.99, 1.52, and 1.45 cm in lateral (LR), longitudinal (SI), and vertical (AP) directions, respectively. The margins required to account for intra-fractional motion were estimated to be 0.19, 0.27, and 0.31 cm in LR, SI and AP directions, respectively. Large intra-fractional shifts were mostly observed in the SI and AP directions, with 2.0 and 5.4% of patients experiencing average intra-fractional motion >3 mm in the SI and AP directions, respectively, compared with none experiencing mean shifts >3 mm in the LR direction. Six patients experienced grade 3 gastrointestinal or genitourinary toxicity. There were no significant differences in mean inter- or intra-fractional motion in any of the cardinal directions compared to patients without severe toxicity (inter-fractional p = 0.46-0.99, intra-fractional p = 0.10-0.84). Conclusion: The inter- and intra-fractional margins estimated from this study are in line with prior reported values. Intra-fractional prostate motion was generally small with larger margins required for the SI and AP directions, notably just slightly exceeding the commonly used 3 mm posterior PTV margin even with realignment between half-arcs. Development of severe toxicity was not significantly associated with the degree of inter- or intra-fractional motion.
- Published
- 2020
12. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
- Author
-
Sandler, Kiri A, Cook, Ryan R, Ciezki, Jay P, Ross, Ashley E, Pomerantz, Mark M, Nguyen, Paul L, Shaikh, Talha, Tran, Phuoc T, Stock, Richard G, Merrick, Gregory S, Demanes, David Jeffrey, Spratt, Daniel E, Abu-Isa, Eyad I, Wedde, Trude B, Lilleby, Wolfgang, Krauss, Daniel J, Shaw, Grace K, Alam, Ridwan, Reddy, Chandana A, Song, Daniel Y, Klein, Eric A, Stephenson, Andrew J, Tosoian, Jeffrey J, Hegde, John V, Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Greco, Stephen C, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Reiter, Robert E, Said, Jonathan W, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, King, Christopher R, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Trials and Supportive Activities ,Prostate Cancer ,Clinical Research ,Urologic Diseases ,Aging ,Aged ,Brachytherapy ,Hemibody Irradiation ,Humans ,Male ,Neoplasm Grading ,Pelvis ,Prostate ,Prostatic Neoplasms ,Retrospective Studies ,Survival Rate ,Gleason grade group 5 ,Prostate cancer ,Radiation therapy ,Whole-pelvis irradiation ,Urology & Nephrology ,Clinical sciences - Abstract
BackgroundThe role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases.ObjectiveTo assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, setting, and participantsWe identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT+BT).Outcome measurements and statistical analysisBiochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment.Results and limitationsA total of 299 EBRT patients (41%) and 320 EBRT+BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT+BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT+BT groups were 58% and 78%, respectively. The median follow-up was 5.6yr. WPRT was associated with improved bRFS among patients treated with EBRT+BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2-0.9, p=0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6-1.2, p=0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7-1.7, p=0.8 for DMFS and HR 0.7, 95% CI 0.4-1.1, p=0.1 for PCSS), or in the EBRT+BT group (HR 0.6, 95% CI 0.3-1.4, p=0.2 for DMFS and HR 0.5 95% CI 0.2-1.2, p=0.1 for PCSS).ConclusionsWPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT+BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT+BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted.Patient summaryWhen men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy.
- Published
- 2020
13. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy.
- Author
-
Valle, Luca F, Ruan, Dan, Dang, Audrey, Levin-Epstein, Rebecca G, Patel, Ankur P, Weidhaas, Joanne B, Nickols, Nicholas G, Lee, Percy P, Low, Daniel A, Qi, X Sharon, King, Christopher R, Steinberg, Michael L, Kupelian, Patrick A, Cao, Minsong, and Kishan, Amar U
- Subjects
dose volume histogram ,late toxicity ,machine learning ,multivariate ,prediction model ,prostate cancer ,stereotactic body radiation therapy ,Oncology and Carcinogenesis - Abstract
Purpose: Dosimetric predictors of toxicity after Stereotactic Body Radiation Therapy (SBRT) are not well-established. We sought to develop a multivariate model that predicts Common Terminology Criteria for Adverse Events (CTCAE) late grade 2 or greater genitourinary (GU) toxicity by interrogating the entire dose-volume histogram (DVH) from a large cohort of prostate cancer patients treated with SBRT on prospective trials. Methods: Three hundred and thirty-nine patients with late CTCAE toxicity data treated with prostate SBRT were identified and analyzed. All patients received 40 Gy in five fractions, every other day, using volumetric modulated arc therapy. For each patient, we examined 910 candidate dosimetric features including maximum dose, volumes of each organ [CTV, organs at risk (OARs)], V100%, and other granular volumetric/dosimetric indices at varying volumetric/dosimetric values from the entire DVH as well as ADT use to model and predict toxicity from SBRT. Training and validation subsets were generated with 90 and 10% of the patients in our cohort, respectively. Predictive accuracy was assessed by calculating the area under the receiver operating curve (AROC). Univariate analysis with student t-test was first performed on each candidate DVH feature. We subsequently performed advanced machine-learning multivariate analyses including classification and regression tree (CART), random forest, boosted tree, and multilayer neural network. Results: Median follow-up time was 32.3 months (range 3-98.9 months). Late grade ≥2 GU toxicity occurred in 20.1% of patients in our series. No single dosimetric parameter had an AROC for predicting late grade ≥2 GU toxicity on univariate analysis that exceeded 0.599. Optimized CART modestly improved prediction accuracy, with an AROC of 0.601, whereas other machine learning approaches did not improve upon univariate analyses. Conclusions: CART-based machine learning multivariate analyses drawing from 910 dosimetric features and ADT use modestly improves upon clinical prediction of late GU toxicity alone, yielding an AROC of 0.601. Biologic predictors may enhance predictive models for identifying patients at risk for late toxicity after SBRT.
- Published
- 2020
14. Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014)
- Author
-
Wang, Chenyang, Kishan, Amar U, Yu, James B, Raldow, Ann, King, Christopher R, Iwamoto, Keisuke S, Chu, Fang-I, Steinberg, Michael L, and Kupelian, Patrick A
- Subjects
Cancer ,Prevention ,Dental/Oral and Craniofacial Disease ,Rare Diseases ,Clinical Research - Abstract
PurposeSecond malignancies (SMs) after radiation therapy are rare but serious sequelae of treatment. This study investigates whether radiation therapy use is associated with changes in baseline SM risk.Methods and materialsWe extracted all patients with cancer, with or without SM, in the Surveillance, Epidemiology, and End Results database from 1973 to 2014. Cumulative incidence of SM for patients stratified by radiation therapy status was calculated using a competing risk model, both for the entire cohort and for subgroups based on the primary tumor's anatomic location.ResultsWe identified 2,872,063 patients with cancer, including 761,289 patients who received radiation therapy and 2,110,774 who did not. The SM rate at 20 years for patients receiving radiation therapy versus no radiation therapy was 21.4% versus 18.8%. The relative risk for SM associated with radiation therapy for the overall group was 1.138 at 20 years. The relative risks for SM associated with radiation therapy to malignancies arising from central nervous system and orbits, head and neck, thorax, abdomen, and pelvis at 20 years were 0.704, 1.011, 0.559, 0.646, and 1.106 for men and 0.792, 1.298, 1.265, 0.780, and 0.988 for women, respectively.ConclusionsThe association between SM and radiation therapy varies with both sex and disease anatomic location, with the largest increase in SM seen in females irradiated to the head and neck region. Overall, the absolute change in SM rates associated with radiation therapy remains small, with differences in various clinical contexts.
- Published
- 2019
15. Radiation Therapy for Prostate Cancer Using HYpofractionation Directed by UltraSound (RAPHYDUS): A Brazilian Public Health Care System Study
- Author
-
Faustino, Fabio de Lima Costa, Altei, Wanessa Fernanda, Canton, Heloisa Pelisser, Morato, Leonardo, Jorge de Paula, Livia Loami Ruys, Salvador, Gabriela Bernal, Fonseca, Diego de Souza Lima, Gonçalves, Thais Kapp, Kupelian, Patrick A., Zaparolli, Jose Carlos, Ercolin, Laura, and Marconi, Daniel Grossi
- Published
- 2022
- Full Text
- View/download PDF
16. RapidPlan hippocampal sparing whole brain model version 2—how far can we reduce the dose?
- Author
-
Liu, Hefei, Clark, Ryan, Magliari, Anthony, Foster, Robert, Reynoso, Francisco, Schmidt, Matthew, Gondi, Vinai, Abraham, Christopher, Curry, Heather, Kupelian, Patrick, Khuntia, Deepak, and Beriwal, Sushil
- Published
- 2022
- Full Text
- View/download PDF
17. Image-Guided Radiotherapy in Lung Cancer
- Author
-
Weng, Julius, primary, Kupelian, Patrick, additional, and Lee, Percy, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients
- Author
-
van Dams, Ritchell, Jiang, Naomi Y., Fuller, Donald B., Loblaw, Andrew, Jiang, Tommy, Katz, Alan J., Collins, Sean P., Aghdam, Nima, Suy, Simeng, Stephans, Kevin L., Yuan, Ye, Nickols, Nicholas G., Murthy, Vedang, Telkhade, Tejshri P., Kupelian, Patrick A., Steinberg, Michael L., Romero, Tahmineh, and Kishan, Amar U.
- Published
- 2021
- Full Text
- View/download PDF
19. Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation
- Author
-
Qi, Xiangrong Sharon, Pajonk, Frank, McCloskey, Susan, Low, Daniel A, Kupelian, Patrick, Steinberg, Michael, and Sheng, Ke
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Stem Cell Research - Nonembryonic - Non-Human ,Cancer ,Breast Cancer ,Stem Cell Research ,Breast ,Breast Neoplasms ,Cell Line ,Tumor ,Cell Survival ,Dose Fractionation ,Radiation ,Female ,Humans ,Neoplastic Stem Cells ,Radiation Tolerance ,Cancer stem cell ,Tumor cell ,Radioresistance ,Linear-quadratic model ,Dual-compartment model ,Other Physical Sciences ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis ,Medical and biological physics - Abstract
Background and purposeGrowing evidence suggested the coexistence of cancer stem cells (CSCs) within solid tumors. We aimed to study radiosensitivity parameters for the CSCs and differentiated tumor cells (TCs) and the correlation of the fractions of CSCs to the overall tumor radioresistance.Material and methodsSurviving fractions of breast cancer cell lines were analyzed using a dual-compartment Linear-quadratic model with independent fitting parameters: radiosensitive αTC, βTC, αCSC, βCSC, and fraction of CSCs f. The overall tumor radio-resistance, the biological effective doses and tumor control probability were estimated as a function of CSC fraction for different fractionation regimens. The pooled clinical outcome data were fitted to the single- and dual-compartment linear-quadric models.ResultsCSCs were more radioresistant characterized by smaller α compared to TCs: αTC=0.1±0.2, αCSC=0.04±0.07 for MCF-7 (f=0.1%), αTC=0.08±0.25, αCSC=0.04±0.18 for SUM159PT (f=2.46%). Higher f values were correlated with increasing radioresistance in cell lines. Analysis of clinical outcome data is in accordance of a dual-compartment CSC model prediction. Higher percentage of BCSCs resulted in more overall tumor radioresistance and less biological effectiveness.ConclusionsPercentage of CSCs strongly correlated to overall tumor radioresistance. This observation suggested potential individualized radiotherapy to account for heterogeneous population of CSCs and their distinct radiosensitivity for breast cancer.
- Published
- 2017
20. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
- Author
-
Chen, Allen M, Felix, Carol, Wang, Pin-Chieh, Hsu, Sophia, Basehart, Vincent, Garst, Jordan, Beron, Phillip, Wong, Deborah, Rosove, Michael H, Rao, Shyam, Melanson, Heather, Kim, Edward, Palmer, Daphne, Qi, Lihong, Kelly, Karen, Steinberg, Michael L, Kupelian, Patrick A, and Daly, Megan E
- Subjects
Humans ,Papillomavirus Infections ,Carcinoma ,Squamous Cell ,Oropharyngeal Neoplasms ,Neoplasm Metastasis ,Neoplasm Recurrence ,Local ,Deglutition Disorders ,Leukopenia ,Neutropenia ,Paclitaxel ,Carboplatin ,Antineoplastic Combined Chemotherapy Protocols ,Neoplasm Staging ,Disease-Free Survival ,Radiotherapy Dosage ,Survival Rate ,Follow-Up Studies ,Aged ,Middle Aged ,Male ,Mucositis ,Human papillomavirus 16 ,Chemoradiotherapy ,Induction Chemotherapy ,Response Evaluation Criteria in Solid Tumors ,Sexually Transmitted Infections ,Clinical Trials and Supportive Activities ,Cancer ,Infectious Diseases ,Clinical Research ,Patient Safety ,Dental/Oral and Craniofacial Disease ,Prevention ,6.5 Radiotherapy and other non-invasive therapies ,6.1 Pharmaceuticals ,Oncology & Carcinogenesis ,Oncology and Carcinogenesis - Abstract
BackgroundHead and neck cancers positive for human papillomavirus (HPV) are exquisitely radiosensitive. We investigated whether chemoradiotherapy with reduced-dose radiation would maintain survival outcomes while improving tolerability for patients with HPV-positive oropharyngeal carcinoma.MethodsWe did a single-arm, phase 2 trial at two academic hospitals in the USA, enrolling patients with newly diagnosed, biopsy-proven stage III or IV squamous-cell carcinoma of the oropharynx, positive for HPV by p16 testing, and with Zubrod performance status scores of 0 or 1. Patients received two cycles of induction chemotherapy with 175 mg/m2 paclitaxel and carboplatin (target area under the curve of 6) given 21 days apart, followed by intensity-modulated radiotherapy with daily image guidance plus 30 mg/m2 paclitaxel per week concomitantly. Complete or partial responders to induction chemotherapy received 54 Gy in 27 fractions, and those with less than partial or no responses received 60 Gy in 30 fractions. The primary endpoint was progression-free survival at 2 years, assessed in all eligible patients who completed protocol treatment. This study is registered with ClinicalTrials.gov, numbers NCT02048020 and NCT01716195.FindingsBetween Oct 4, 2012, and March 3, 2015, 45 patients were enrolled with a median age of 60 years (IQR 54-67). One patient did not receive treatment and 44 were included in the analysis. 24 (55%) patients with complete or partial responses to induction chemotherapy received 54 Gy radiation, and 20 (45%) with less than partial responses received 60 Gy. Median follow-up was 30 months (IQR 26-37). Three (7%) patients had locoregional recurrence and one (2%) had distant metastasis; 2-year progression-free survival was 92% (95% CI 77-97). 26 (39%) of 44 patients had grade 3 adverse events, but no grade 4 events were reported. The most common grade 3 events during induction chemotherapy were leucopenia (17 [39%]) and neutropenia (five [11%]), and during chemoradiotherapy were dysphagia (four [9%]) and mucositis (four [9%]). One (2%) of 44 patients was dependent on a gastrostomy tube at 3 months and none was dependent 6 months after treatment.InterpretationChemoradiotherapy with radiation doses reduced by 15-20% was associated with high progression-free survival and an improved toxicity profile compared with historical regimens using standard doses. Radiotherapy de-escalation has the potential to improve the therapeutic ratio and long-term function for these patients.FundingUniversity of California.
- Published
- 2017
21. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
- Author
-
Kishan, Amar U, Shaikh, Talha, Wang, Pin-Chieh, Reiter, Robert E, Said, Jonathan, Raghavan, Govind, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Kamrava, Mitchell, Demanes, David Jeffrey, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, and King, Christopher R
- Subjects
Humans ,Adenocarcinoma ,Prostatic Neoplasms ,Neoplasm Metastasis ,Androgen Antagonists ,Prognosis ,Treatment Failure ,Radiotherapy ,Brachytherapy ,Prostatectomy ,Multivariate Analysis ,Proportional Hazards Models ,Retrospective Studies ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Male ,Kaplan-Meier Estimate ,Neoplasm Grading ,Gleason 10 ,Gleason 9 ,Radical prostatectomy ,Prostate Cancer ,Rare Diseases ,Patient Safety ,Urologic Diseases ,Clinical Research ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Clinical Sciences ,Urology & Nephrology - Abstract
BackgroundThe long natural history of prostate cancer (CaP) limits comparisons of efficacy between radical prostatectomy (RP) and external beam radiotherapy (EBRT), since patients treated years ago received treatments considered suboptimal by modern standards (particularly with regards to androgen deprivation therapy [ADT] and radiotherapy dose-escalation]. Gleason score (GS) 9-10 CaP is particularly aggressive, and clinically-relevant endpoints occur early, facilitating meaningful comparisons.ObjectiveTo compare outcomes of patients with GS 9-10 CaP following EBRT, extremely-dose escalated radiotherapy (as exemplified by EBRT+brachytherapy [EBRT+BT]), and RP.Design, setting, participantsRetrospective analysis of 487 patients with biopsy GS 9-10 CaP treated between 2000 and 2013 (230 with EBRT, 87 with EBRT+BT, and 170 with RP). Most radiotherapy patients received ADT and dose-escalated radiotherapy.Outcome measurements and statistical analysisKaplan-Meier analysis and multivariate Cox regression estimated and compared 5-yr and 10-yr rates of distant metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS).Results and limitationsThe median follow-up was 4.6 yr. Local salvage and systemic salvage were performed more frequently in RP patients (49.0% and 30.1%) when compared with either EBRT patients (0.9% and 19.7%) or EBRT+BT patients (1.2% and 16.1%, p
- Published
- 2017
22. A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer
- Author
-
Ritter, Mark A., Kupelian, Patrick A., Petereit, Daniel G., Lawton, Colleen A., Anger, Nick, Geye, Heather, Chappell, Richard J., and Forman, Jeffrey D.
- Published
- 2020
- Full Text
- View/download PDF
23. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
- Author
-
Shaverdian, Narek, Tenn, Stephen, Veruttipong, Darlene, Wang, Jason, Hegde, John, Lee, Chul, Cao, Minsong, Agazaryan, Nzhde, Steinberg, Michael, Kupelian, Patrick, and Lee, Percy
- Subjects
Lung ,Humans ,Carcinoma ,Non-Small-Cell Lung ,Lung Neoplasms ,Treatment Outcome ,Radiosurgery ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Retrospective Studies ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Four-Dimensional Computed Tomography ,Kaplan-Meier Estimate ,Clinical Research ,Cancer ,Lung Cancer ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
ObjectiveWe evaluated whether patients with early-stage non-small-cell lung cancers (NSCLCs) treated with stereotactic body radiation therapy (SBRT) without full prescription dose coverage of the planning target volume (PTV) had inferior outcomes.MethodsThe SBRT regimen was 54 Gy in three fractions. Dosimetric constraints were as per the Radiation Therapy Oncology Group 0236 guidelines. All patients underwent four-dimensional CT (4D-CT) simulation. The internal target volume (ITV) was defined using 4D-CT, and the PTV was defined as a 6-mm longitudinal and a 3-mm axial expansion from the ITV. If normal tissue constraints were beyond tolerance, ITV-based dosing was employed where priority was made for full ITV coverage at the expense of PTV coverage. Patients with and without full PTV dose coverage were compared, and control rates were estimated using Kaplan-Meier analysis.Results120 NSCLC cases were evaluated with 81% having adequate PTV dose coverage. ITV and PTV were significantly larger in the cohort with inadequate PTV dose coverage (p = 0.0085 and p = 0.0038, respectively), and the mean ITV and PTV doses were higher in patients with adequate PTV dose coverage (p = 0.002 and p
- Published
- 2016
24. Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases
- Author
-
Marconi, Daniel Grossi, da Costa Resende, Bruno, Rauber, Erick, de Cassia Soares, Paula, Fernandes, Jose Maria, Mehta, Niraj, Carvalho, Andre Lopes, Kupelian, Patrick A, and Chen, Allen
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Cancer ,Adult ,Aged ,Dose Fractionation ,Radiation ,Female ,Head and Neck Neoplasms ,Humans ,Male ,Middle Aged ,Retrospective Studies ,Skin Neoplasms ,Treatment Failure ,X-Ray Therapy ,General Science & Technology - Abstract
IntroductionTo report a single-institutional experience with the use of Superficial X-Ray Therapy (SXRT) for head and neck non-melanoma skin cancer (N-MSC) and to compare outcomes by prescribed fractionation schedules.Materials and methodsThe medical records of 597 patients with 1021 lesions (720 BCC, 242 SCC, 59 SCC in situ) treated with kilovoltage radiation from 1979-2013 were retrospectively reviewed. The majority of patients were treated according to 1 of 3 institutional protocols based on the discretion of the radiation oncologist: 1) 22 x 2.5 Gy; 2) 20 x 2.5 Gy; 3) 30 x 2.0 Gy. "T" stage at first presentation was as follows: Tis (59); T1 (765); T2 (175); T3 (6), T4 (9); Tx, (7). All patients were clinical N0 and M0 at presentation. Chi-square test was used to evaluate any potential association between variables. The Kaplan-Meier method was used to analyze survival with the Log Rank test used for comparison. A Cox Regression analysis was performed for multivariate analysis.ResultsThe median follow up was 44 months. No significant difference was observed among the 3 prescribed fractionation schemes (p = 0.78) in terms of RTOG toxicity. There were no failures among SCC in situ, 37 local failures (23 BCC, 14 SCC), 5 regional failures (all SCC) and 2 distant failures (both SCC). For BCC, the 5-year LC was 96% and the 10-year LC was 94%. For SCC the corresponding rates of local control were 92% and 87%, respectively (p = 0.03). The use of >2.0 Gy daily was significantly associated with improved LC on multivariate analysis (HR: 0.17; CI 95%: 0.05-0.59).ConclusionSXRT for N-MSC of the head and neck is well tolerated, achieves excellent local control, and should continue to be recommended in the management of this disease. Fractionation schedules using >2.0 Gy daily appear to be associated with improved LC.
- Published
- 2016
25. Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases.
- Author
-
Grossi Marconi, Daniel, da Costa Resende, Bruno, Rauber, Erick, de Cassia Soares, Paula, Fernandes, Jose Maria, Mehta, Niraj, Lopes Carvalho, Andre, Kupelian, Patrick A, and Chen, Allen
- Subjects
Humans ,Head and Neck Neoplasms ,Skin Neoplasms ,Treatment Failure ,X-Ray Therapy ,Retrospective Studies ,Adult ,Aged ,Middle Aged ,Female ,Male ,Dose Fractionation ,Radiation ,Cancer ,Clinical Research ,General Science & Technology - Abstract
IntroductionTo report a single-institutional experience with the use of Superficial X-Ray Therapy (SXRT) for head and neck non-melanoma skin cancer (N-MSC) and to compare outcomes by prescribed fractionation schedules.Materials and methodsThe medical records of 597 patients with 1021 lesions (720 BCC, 242 SCC, 59 SCC in situ) treated with kilovoltage radiation from 1979-2013 were retrospectively reviewed. The majority of patients were treated according to 1 of 3 institutional protocols based on the discretion of the radiation oncologist: 1) 22 x 2.5 Gy; 2) 20 x 2.5 Gy; 3) 30 x 2.0 Gy. "T" stage at first presentation was as follows: Tis (59); T1 (765); T2 (175); T3 (6), T4 (9); Tx, (7). All patients were clinical N0 and M0 at presentation. Chi-square test was used to evaluate any potential association between variables. The Kaplan-Meier method was used to analyze survival with the Log Rank test used for comparison. A Cox Regression analysis was performed for multivariate analysis.ResultsThe median follow up was 44 months. No significant difference was observed among the 3 prescribed fractionation schemes (p = 0.78) in terms of RTOG toxicity. There were no failures among SCC in situ, 37 local failures (23 BCC, 14 SCC), 5 regional failures (all SCC) and 2 distant failures (both SCC). For BCC, the 5-year LC was 96% and the 10-year LC was 94%. For SCC the corresponding rates of local control were 92% and 87%, respectively (p = 0.03). The use of >2.0 Gy daily was significantly associated with improved LC on multivariate analysis (HR: 0.17; CI 95%: 0.05-0.59).ConclusionSXRT for N-MSC of the head and neck is well tolerated, achieves excellent local control, and should continue to be recommended in the management of this disease. Fractionation schedules using >2.0 Gy daily appear to be associated with improved LC.
- Published
- 2016
26. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy
- Author
-
Kishan, Amar U, Park, Sang J, King, Christopher R, Roberts, Kristofer, Kupelian, Patrick A, Steinberg, Michael L, and Kamrava, Mitchell
- Subjects
Urologic Diseases ,Cancer ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Humans ,Male ,Organs at Risk ,Penis ,Prostate ,Prostatic Neoplasms ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Radiotherapy ,Intensity-Modulated ,Rectum ,Urethra ,Urinary Bladder ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
ObjectiveCompared with standard, whole-gland (WG) therapies for prostate cancer, focal approaches may provide equivalent oncologic outcomes with fewer adverse effects. The purpose of this study was to compare organ-at-risk (OAR) dosimetry between hemigland (HG) and WG stereotactic body radiotherapy (SBRT) plans.MethodsVolumetric-modulated arc radiotherapy-based SBRT plans were designed to treat the left HG, right HG and WG in eight patients, using five fractions of 8 Gy. OARs of interest included the contralateral HG, rectum, urinary bladder, urethra, penile bulb and contralateral neurovascular bundle.ResultsRectal V80% (the percentage of a normal structure receiving a dose of 80%) and V90% were significantly lower with HG plans than with WG plans (median values of 4.4 vs 2.5 cm(3) and 2.1 vs 1.1 cm(3), respectively, p
- Published
- 2015
27. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer
- Author
-
Kamrava, Mitchell, Kishan, Amar U, Margolis, Daniel J, Huang, Jiaoti, Dorey, Fred, Lieu, Patricia, Kupelian, Patrick A, and Marks, Leonard S
- Subjects
Clinical Research ,Biomedical Imaging ,Urologic Diseases ,Aging ,Cancer ,Prevention ,Prostate Cancer ,4.2 Evaluation of markers and technologies ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Disease Management ,Humans ,Image-Guided Biopsy ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Neoplasm Staging ,Prognosis ,Prostatic Neoplasms ,Risk Factors ,Ultrasonography - Abstract
PurposeMagnetic resonance imaging (MRI) guidance may improve the accuracy of Gleason score (GS) determination by directing the biopsy to regions of interest (ROI) that are likely to harbor high-grade prostate cancer (CaP). The aim of this study was to determine the frequency and predictors of GS upgrading when a subsequent MRI-guided biopsy is performed on patients with a diagnosis of GS 6 disease on the basis of conventional, transrectal ultrasound-guided biopsy.Methods and materialsA consecutive series of 245 men with a diagnosis of low-risk CaP (ie, cT1c, GS 6, prostate-specific antigen
- Published
- 2015
28. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy
- Author
-
Jiang, Naomi Y., Dang, Audrey T., Yuan, Ye, Chu, Fang-I, Shabsovich, David, King, Christopher R., Collins, Sean P., Aghdam, Nima, Suy, Simeng, Mantz, Constantine A., Miszczyk, Leszek, Napieralska, Aleksandra, Namysl-Kaletka, Agnieszka, Bagshaw, Hilary, Prionas, Nicolas, Buyyounouski, Mark K., Jackson, William C., Spratt, Daniel E., Nickols, Nicholas G., Steinberg, Michael L., Kupelian, Patrick A., and Kishan, Amar U.
- Published
- 2019
- Full Text
- View/download PDF
29. Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy
- Author
-
Nguyen, Dan, Rwigema, Jean-Claude M, Yu, Victoria Y, Kaprealian, Tania, Kupelian, Patrick, Selch, Michael, Lee, Percy, Low, Daniel A, and Sheng, Ke
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Brain Cancer ,Neurosciences ,Cancer ,Clinical Research ,Brain Disorders ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Adult ,Aged ,Brain Neoplasms ,Feasibility Studies ,Female ,Follow-Up Studies ,Glioblastoma ,Humans ,Male ,Middle Aged ,Organs at Risk ,Particle Accelerators ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Radiotherapy ,Intensity-Modulated ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundGlioblastoma multiforme (GBM) frequently recurs at the same location after radiotherapy. Further dose escalation using conventional methods is limited by normal tissue tolerance. 4π non-coplanar radiotherapy has recently emerged as a new potential method to deliver highly conformal radiation dose using the C-arm linacs. We aim to study the feasibility of very substantial GBM dose escalation while maintaining normal tissue tolerance using 4π.Methods11 GBM patients previously treated with volumetric modulated arc therapy (VMAT/RapidArc) on the NovalisTx™ platform to a prescription dose of either 59.4 Gy or 60 Gy were included. All patients were replanned with 30 non-coplanar beams using a 4π radiotherapy platform, which inverse optimizes both beam angles and fluence maps. Four different prescriptions were used including original prescription dose and PTV (4πPTVPD), 100 Gy to the PTV and GTV (4πPTV100Gy), 100 Gy to the GTV only while maintaining prescription dose to the rest of the PTV (4πGTV100Gy), and a 5 mm margin expansion plan (4πPTVPD+5mm). OARs included in the study are the normal brain (brain - PTV), brainstem, chiasm, spinal cord, eyes, lenses, optical nerves, and cochleae.ResultsThe 4π plans resulted in superior dose gradient indices, as indicated by >20% reduction in the R50, compared to the clinical plans. Among all of the 4π cases, when compared to the clinical plans, the maximum and mean doses were significantly reduced (p 0.05) for all of the non-brain OARs. Both the 4πPTVPD and 4π GTV100GYplans reduced the mean normal brain mean doses.Conclusions4π non-coplanar radiotherapy substantially increases the dose gradient outside of the PTV and better spares critical organs. Dose escalation to 100 Gy to the GTV or additional margin expansion while meeting clinical critical organ dose constraints is feasible. 100 Gy to the PTV result in higher normal brain doses but may be tolerated when delivered in proportionally increased treatment fractions. Therefore, 4π non-coplanar radiotherapy on C-arm gantry may provide an accessible tool to improve the outcome of GBM radiotherapy through extreme dose escalation.
- Published
- 2014
30. Enhancing Career Paths for Tomorrow's Radiation Oncologists
- Author
-
Vapiwala, Neha, Thomas, Charles R., Jr., Grover, Surbhi, Yap, Mei Ling, Mitin, Timur, Shulman, Lawrence N., Gospodarowicz, Mary K., Longo, John, Petereit, Daniel G., Ennis, Ronald D., Hayman, James A., Rodin, Danielle, Buchsbaum, Jeffrey C., Vikram, Bhadrasain, Abdel-Wahab, May, Epstein, Alan H., Okunieff, Paul, Goldwein, Joel, Kupelian, Patrick, Weidhaas, Joanne B., Tucker, Margaret A., Boice, John D., Jr., Fuller, Clifton David, Thompson, Reid F., Trister, Andrew D., Formenti, Silvia C., Barcellos-Hoff, Mary-Helen, Jones, Joshua, Dharmarajan, Kavita V., Zietman, Anthony L., and Coleman, C. Norman
- Published
- 2019
- Full Text
- View/download PDF
31. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials
- Author
-
Yuan, Ye, Aghdam, Nima, King, Christopher R., Fuller, Donald B., Weng, Julius, Chu, Fang-I., Mardirossian, George, Patel, Ankur, Nickols, Nicholas G., Kupelian, Patrick A., Steinberg, Michael L., Collins, Sean P., and Kishan, Amar U.
- Published
- 2019
- Full Text
- View/download PDF
32. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer
- Author
-
Abu-Gheida, Ibrahim, Reddy, Chandana A., Kotecha, Rupesh, Weller, Michael A., Shah, Chirag, Kupelian, Patrick A., Mian, Omar, Ciezki, Jay P., Stephans, Kevin L., and Tendulkar, Rahul D.
- Published
- 2019
- Full Text
- View/download PDF
33. Multiparametric MRI identifies and stratifies prostate cancer lesions: Implications for targeting intraprostatic targets
- Author
-
Anderson, Erik S, Margolis, Daniel JA, Mesko, Shane, Banerjee, Robyn, Wang, Pin-Chieh, Demanes, D Jeffrey, Kupelian, Patrick, and Kamrava, Mitchell
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Prevention ,Biomedical Imaging ,Aging ,Cancer ,Urologic Diseases ,Prostate Cancer ,Adenocarcinoma ,Adult ,Aged ,Brachytherapy ,Humans ,Image-Guided Biopsy ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Poisson Distribution ,Prostatic Neoplasms ,Retrospective Studies ,Multiparametric MRI ,Prostate cancer ,mp-MRI scoring ,Index lesion ,MRI-based planning ,Oncology & Carcinogenesis ,Clinical sciences - Abstract
PurposeTo assess the ability of multiparametric (mp) MRI (mp-MRI) to identify, stratify, and localize biopsy-proven prostate cancer lesions in a risk-stratified patient population.Methods and materialsWe retrospectively analyzed 57 patients who had mp-MRI and core needle biopsy during diagnostic prostate cancer evaluation. The MRI sequences were scored for suspicion of cancer with a previously described system. Distributions of mp-MRI scores were compared across National Comprehensive Cancer Network prostate cancer risk groups. The mp-MRI-identified lesions were compared with the location of positive core needle biopsies to assess mp-MRI localization of true lesions.ResultsThe mp-MRI scoring system identified lesions in 84% (48/57) of the patients, including 100% (12/12) in the high-risk group. Scores assigned to lesions in patients in intermediate- and high-risk groups were statistically higher than those in the low-risk group, with a relative risk of 6.72 (95% confidence interval: 2.32-19.51, p
- Published
- 2014
34. Accelerating Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Tracking Based on Low-Rank Decomposition in the Spatial–Temporal Domain: A Feasibility Study Based on Simulation and Preliminary Prospective Undersampled MRI
- Author
-
Sarma, Manoj, Hu, Peng, Rapacchi, Stanislas, Ennis, Daniel, Thomas, Albert, Lee, Percy, Kupelian, Patrick, and Sheng, Ke
- Subjects
Medical and Biological Physics ,Physical Sciences ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Biomedical Imaging ,Bioengineering ,Cancer ,Feasibility Studies ,Humans ,Image Enhancement ,Image Processing ,Computer-Assisted ,Lung Neoplasms ,Magnetic Resonance Imaging ,Movement ,Respiration ,Retrospective Studies ,Other Physical Sciences ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeTo evaluate a low-rank decomposition method to reconstruct down-sampled k-space data for the purpose of tumor tracking.Methods and materialsSeven retrospective lung cancer patients were included in the simulation study. The fully-sampled k-space data were first generated from existing 2-dimensional dynamic MR images and then down-sampled by 5 × -20 × before reconstruction using a Cartesian undersampling mask. Two methods, a low-rank decomposition method using combined dynamic MR images (k-t SLR based on sparsity and low-rank penalties) and a total variation (TV) method using individual dynamic MR frames, were used to reconstruct images. The tumor trajectories were derived on the basis of autosegmentation of the resultant images. To further test its feasibility, k-t SLR was used to reconstruct prospective data of a healthy subject. An undersampled balanced steady-state free precession sequence with the same undersampling mask was used to acquire the imaging data.ResultsIn the simulation study, higher imaging fidelity and low noise levels were achieved with the k-t SLR compared with TV. At 10 × undersampling, the k-t SLR method resulted in an average normalized mean square error 1 mm with 10 × down-sampling using k-t SLR, as opposed to 17% using TV. In the prospective study, k-t SLR substantially reduced reconstruction artifacts and retained anatomic details.ConclusionsMagnetic resonance reconstruction using k-t SLR on highly undersampled dynamic MR imaging data results in high image quality useful for tumor tracking. The k-t SLR was superior to TV by better exploiting the intrinsic anatomic coherence of the same patient. The feasibility of k-t SLR was demonstrated by prospective imaging acquisition and reconstruction.
- Published
- 2014
35. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
- Author
-
Wu, Trudy C., Luterstein, Elaine, Neilsen, Beth K., Goldman, Jonathan W., Garon, Edward B., Lee, Jay M., Felix, Carol, Cao, Minsong, Tenn, Stephen E., Low, Daniel A., Kupelian, Patrick A., Steinberg, Michael L., and Lee, Percy
- Published
- 2024
- Full Text
- View/download PDF
36. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology
- Author
-
Sandler, Kiri A., Mitchell, Sandra A., Basch, Ethan, Raldow, Ann C., Steinberg, Michael L., Sharif, Jamal, Cook, Ryan R., Kupelian, Patrick A., and McCloskey, Susan A.
- Published
- 2018
- Full Text
- View/download PDF
37. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
- Author
-
Sandler, Kiri A., Cook, Ryan R., Ciezki, Jay P., Ross, Ashley E., Pomerantz, Mark M., Nguyen, Paul L., Shaikh, Talha, Tran, Phuoc T., Stock, Richard G., Merrick, Gregory S., Demanes, D. Jeffrey, Spratt, Daniel E., Abu-Isa, Eyad I., Wedde, Trude B., Lilleby, Wolfgang, Krauss, Daniel J., Shaw, Grace K., Alam, Ridwan, Reddy, Chandana A., Song, Daniel Y., Klein, Eric A., Stephenson, Andrew J., Tosoian, Jeffrey J., Hegde, John V., Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V., Nickols, Nicholas G., Aronson, William J., Sadeghi, Ahmad, Greco, Stephen C., Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L., Reiter, Robert E., Said, Jonathan W., Steinberg, Michael L., Horwitz, Eric M., Kupelian, Patrick A., King, Christopher R., and Kishan, Amar U.
- Published
- 2018
- Full Text
- View/download PDF
38. Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment
- Author
-
Kamrava, Mitchell, Chung, Melody P, Kayode, Oluwatosin, Wang, Jason, Marks, Leonard, Kupelian, Patrick, Steinberg, Michael, Park, Sang-June, and Demanes, D Jeffrey
- Subjects
Clinical Research ,Urologic Diseases ,Brachytherapy ,Dose-Response Relationship ,Radiation ,Follow-Up Studies ,Humans ,Male ,Organs at Risk ,Prostatic Neoplasms ,Radiometry ,Radiotherapy Planning ,Computer-Assisted ,Radiotherapy ,High-Energy ,Rectum ,Time Factors ,Urinary Bladder ,Prostate ,Focal therapy ,Clinical Sciences ,Oncology & Carcinogenesis - Abstract
PurposeTo determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment.Methods and materialsA total of 10 WG implants were used to generate 10 WG and 20 HG (left and right) treatment plans optimized with the inverse planning simulation annealing algorithm using Oncentra MasterPlan (Nucletron B.V., Veenendaal, The Netherlands). The standard distribution of 17-18 catheters designed for WG was used to generate HG plans. The same OARs namely bladder, rectum, and urethra contours and dose constraints were applied for HG and WG plans. The HG contour was a modification of the WG contour whereby the urethra divided the prostate into HGs. The prescription dose was 7.25 Gy×6. Evaluated dose parameters were target dose D90, V100, and V150 and D0.1 cc, D1 cc, and D2 cc to OARs.ResultsThe HG plans had a D90, V100, and V150 to the HG target of 112%, 97.6%, and 33.8%, respectively. The WG plans had a D90, V100, and V150 to the WG target of 108%, 98.8%, and 26.5%, respectively. The OAR D2 cc doses were significantly lower in HG vs. WG plans: rectum (53.1% vs. 64.1%, p
- Published
- 2013
39. A client–server framework for 3D remote visualization of radiotherapy treatment space
- Author
-
Santhanam, Anand P, Min, Yugang, Dou, Tai H, Kupelian, Patrick, and Low, Daniel A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cancer ,3D monitoring ,client–server architecture ,patient positioning ,radiotherapy ,remote visualization ,Oncology and Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Radiotherapy is safely employed for treating wide variety of cancers. The radiotherapy workflow includes a precise positioning of the patient in the intended treatment position. While trained radiation therapists conduct patient positioning, consultation is occasionally required from other experts, including the radiation oncologist, dosimetrist, or medical physicist. In many circumstances, including rural clinics and developing countries, this expertise is not immediately available, so the patient positioning concerns of the treating therapists may not get addressed. In this paper, we present a framework to enable remotely located experts to virtually collaborate and be present inside the 3D treatment room when necessary. A multi-3D camera framework was used for acquiring the 3D treatment space. A client-server framework enabled the acquired 3D treatment room to be visualized in real-time. The computational tasks that would normally occur on the client side were offloaded to the server side to enable hardware flexibility on the client side. On the server side, a client specific real-time stereo rendering of the 3D treatment room was employed using a scalable multi graphics processing units (GPU) system. The rendered 3D images were then encoded using a GPU-based H.264 encoding for streaming. Results showed that for a stereo image size of 1280 × 960 pixels, experts with high-speed gigabit Ethernet connectivity were able to visualize the treatment space at approximately 81 frames per second. For experts remotely located and using a 100 Mbps network, the treatment space visualization occurred at 8-40 frames per second depending upon the network bandwidth. This work demonstrated the feasibility of remote real-time stereoscopic patient setup visualization, enabling expansion of high quality radiation therapy into challenging environments.
- Published
- 2013
40. Quantifying the ki-67 heterogeneity profile in prostate cancer.
- Author
-
Mesko, Shane, Kupelian, Patrick, Demanes, D Jeffrey, Huang, Jaoti, Wang, Pin-Chieh, and Kamrava, Mitchell
- Subjects
Oncology and Carcinogenesis - Abstract
BackgroundKi-67 is a robust predictive/prognostic marker in prostate cancer; however, tumor heterogeneity in prostate biopsy samples is not well studied.MethodsUsing an MRI/US fusion device, biopsy cores were obtained systematically and by targeting when indicated by MRI. Prostate cores containing cancer from 77 consecutive men were analyzed. The highest Ki-67 was used to determine interprostatic variation. Ki-67 range (highest minus lowest) was used to determine intraprostatic and intralesion variation. Apparent diffusion coefficient (ADC) values were evaluated in relation to Ki-67.ResultsInterprostatic Ki-67 mean ± standard deviation (SD) values for NCCN low (L), intermediate (I), and high (H) risk patients were 5.1 ± 3.8%, 7.4 ± 6.8%, and 12.0 ± 12.4% (ANOVA P = 0.013). Intraprostatic mean ± SD Ki-67 ranges in L, I, and H risk patients were 2.6 ± 3.6%, 5.3 ± 6.8%, and 10.9 ± 12.3% (ANOVA P = 0.027). Intralesion mean ± SD Ki-67 ranges in L, I, and H risk patients were 1.1 ± 0.9%, 5.2 ± 7.9%, and 8.1 ± 10.8% (ANOVA P = 0.22). ADC values at Ki-67 > and
- Published
- 2013
41. Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer
- Author
-
Hunter, Grant K, Reddy, Chandana A, Klein, Eric A, Kupelian, Patrick, Angermeier, Kenneth, Ulchaker, James, Chehade, Nabil, Altman, Andrew, and Ciezki, Jay P
- Subjects
Digestive Diseases ,Cancer ,Urologic Diseases ,Prostate Cancer ,Patient Safety ,Oncology and Carcinogenesis - Abstract
Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525 patients treated in 1999 were reviewed to evaluate toxicity. Late GI and GU morbidities were graded according to the RTOG late morbidity criteria. Other factors examined were patient age, BMI, smoking history, and medical co-morbidities. Due to the low event rate for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results. Median follow-up time was 8.5 years. On CRR univariate analysis, only the presence of DM was significantly associated with GU toxicity grade >2 (P = 0.43, HR 2.35, 95% Cl = 1.03-5.39). On univariate analysis, RT and DM were significantly associated with late GI toxicity. On multivariable analysis, both variables remained significant (RT: P = 0.038, HR = 4.71, CI = 1.09-20.3; DM: P = 0.008, HR = 3.81, 95% Cl = 1.42-10.2). Conclusions. Late effects occur with all treatment modalities. The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP.
- Published
- 2012
42. Prostate intrafraction translation margins for real-time monitoring and correction strategies.
- Author
-
Litzenberg, Dale W, Balter, James M, Hadley, Scott W, Hamstra, Daniel A, Willoughby, Twyla R, Kupelian, Patrick A, Djemil, Toufik, Mahadevan, Arul, Jani, Shirish, Weinstein, Geoffrey, Solberg, Timothy, Enke, Charles, Levine, Lisa, and Sandler, Howard M
- Subjects
Oncology and Carcinogenesis - Abstract
The purpose of this work is to determine appropriate radiation therapy beam margins to account for intrafraction prostate translations for use with real-time electromagnetic position monitoring and correction strategies. Motion was measured continuously in 35 patients over 1157 fractions at 5 institutions. This data was studied using van Herk's formula of (αΣ + γσ') for situations ranging from no electromagnetic guidance to automated real-time corrections. Without electromagnetic guidance, margins of over 10 mm are necessary to ensure 95% dosimetric coverage while automated electromagnetic guidance allows the margins necessary for intrafraction translations to be reduced to submillimeter levels. Factors such as prostate deformation and rotation, which are not included in this analysis, will become the dominant concerns as margins are reduced. Continuous electromagnetic monitoring and automated correction have the potential to reduce prostate margins to 2-3 mm, while ensuring that a higher percentage of patients (99% versus 90%) receive a greater percentage (99% versus 95%) of the prescription dose.
- Published
- 2012
43. Modeling Airflow Using Subject-Specific 4DCT-Based Deformable Volumetric Lung Models.
- Author
-
Ilegbusi, Olusegun J, Li, Zhiliang, Seyfi, Behnaz, Min, Yugang, Meeks, Sanford, Kupelian, Patrick, and Santhanam, Anand P
- Subjects
Nuclear Medicine & Medical Imaging - Abstract
Lung radiotherapy is greatly benefitted when the tumor motion caused by breathing can be modeled. The aim of this paper is to present the importance of using anisotropic and subject-specific tissue elasticity for simulating the airflow inside the lungs. A computational-fluid-dynamics (CFD) based approach is presented to simulate airflow inside a subject-specific deformable lung for modeling lung tumor motion and the motion of the surrounding tissues during radiotherapy. A flow-structure interaction technique is employed that simultaneously models airflow and lung deformation. The lung is modeled as a poroelastic medium with subject-specific anisotropic poroelastic properties on a geometry, which was reconstructed from four-dimensional computed tomography (4DCT) scan datasets of humans with lung cancer. The results include the 3D anisotropic lung deformation for known airflow pattern inside the lungs. The effects of anisotropy are also presented on both the spatiotemporal volumetric lung displacement and the regional lung hysteresis.
- Published
- 2012
44. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer.
- Author
-
Lee, Percy, Kupelian, Patrick, Czernin, Johannes, and Ghosh, Partha
- Subjects
PET/CT ,image-guided radiation therapy ,intensity-modulated radiation therapy ,lung cancer ,radiotherapy planning ,stereotactic body radiation therapy ,Oncology and Carcinogenesis - Abstract
Radiation therapy is an important component of cancer therapy for early stage as well as locally advanced lung cancer. The use of F18 FDG PET/CT has come to the forefront of lung cancer staging and overall treatment decision-making. FDG PET/CT parameters such as standard uptake value and metabolic tumor volume provide important prognostic and predictive information in lung cancer. Importantly, FDG PET/CT for radiation planning has added biological information in defining the gross tumor volume as well as involved nodal disease. For example, accurate target delineation between tumor and atelectasis is facilitated by utilizing PET and CT imaging. Furthermore, there has been meaningful progress in incorporating metabolic information from FDG PET/CT imaging in radiation treatment planning strategies such as radiation dose escalation based on standard uptake value thresholds as well as using respiratory-gated PET and CT planning for improved target delineation of moving targets. In addition, PET/CT-based follow-up after radiation therapy has provided the possibility of early detection of local as well as distant recurrences after treatment. More research is needed to incorporate other biomarkers such as proliferative and hypoxia biomarkers in PET as well as integrating metabolic information in adaptive, patient-centered, tailored radiation therapy.
- Published
- 2012
45. Expanding the use of real-time electromagnetic tracking in radiation oncology.
- Author
-
Shah, Amish P, Kupelian, Patrick A, Willoughby, Twyla R, and Meeks, Sanford L
- Subjects
Humans ,Neoplasms ,Radiotherapy ,Intensity-Modulated ,Electromagnetic Phenomena ,Radiotherapy ,Intensity-Modulated ,Nuclear Medicine & Medical Imaging ,Other Physical Sciences ,Clinical Sciences ,Medical Physiology - Abstract
In the past 10 years, techniques to improve radiotherapy delivery, such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) for both inter- and intrafraction tumor localization, and hypofractionated delivery techniques such as stereotactic body radiation therapy (SBRT), have evolved tremendously. This review article focuses on only one part of that evolution, electromagnetic tracking in radiation therapy. Electromagnetic tracking is still a growing technology in radiation oncology and, as such, the clinical applications are limited, the expense is high, and the reimbursement is insufficient to cover these costs. At the same time, current experience with electromagnetic tracking applied to various clinical tumor sites indicates that the potential benefits of electromagnetic tracking could be significant for patients receiving radiation therapy. Daily use of these tracking systems is minimally invasive and delivers no additional ionizing radiation to the patient, and these systems can provide explicit tumor motion data. Although there are a number of technical and fiscal issues that need to be addressed, electromagnetic tracking systems are expected to play a continued role in improving the precision of radiation delivery.
- Published
- 2011
46. Comparison of transabdominal ultrasound and electromagnetic transponders for prostate localization
- Author
-
Foster, Ryan D, Solberg, Timothy D, Li, Haisen S, Kerkhoff, Andrew, Enke, Charles A, Willoughby, Twyla R, and Kupelian, Patrick A
- Subjects
Medical and Biological Physics ,Biomedical and Clinical Sciences ,Clinical Sciences ,Physical Sciences ,Oncology and Carcinogenesis ,Aging ,Urologic Diseases ,Biomedical Imaging ,Cancer ,Prostate Cancer ,Abdomen ,Electromagnetic Phenomena ,Humans ,Likelihood Functions ,Male ,Movement ,Nebraska ,Prostate ,Prostatic Neoplasms ,Prostheses and Implants ,Radiography ,Reproducibility of Results ,Sensitivity and Specificity ,Skin ,Time Factors ,Ultrasonography ,localization ,prostate ,ultrasound ,electromagnetic transponders ,Other Physical Sciences ,Medical Physiology ,Nuclear Medicine & Medical Imaging ,Medical physiology ,Medical and biological physics - Abstract
The aim of this study is to compare two methodologies of prostate localization in a large cohort of patients. Daily prostate localization using B-mode ultrasound has been performed at the Nebraska Medical Center since 2000. More recently, a technology using electromagnetic transponders implanted within the prostate was introduced into our clinic (Calypso(R)). With each technology, patients were localized initially using skin marks. Localization error distributions were determined from offsets between the initial setup positions and those determined by ultrasound or Calypso. Ultrasound localization data was summarized from 16619 imaging sessions spanning 7 years; Calypso localization data consists of 1524 fractions in 41 prostate patients treated in the course of a clinical trial at five institutions and 640 localizations from the first 16 patients treated with our clinical system. Ultrasound and Calypso patients treated between March and September 2007 at the Nebraska Medical Center were analyzed and compared, allowing a single institutional comparison of the two technologies. In this group of patients, the isocenter determined by ultrasound-based localization is on average 5.3 mm posterior to that determined by Calypso, while the systematic and random errors and PTV margins calculated from the ultrasound localizations were 3 - 4 times smaller than those calculated from the Calypso localizations. Our study finds that there are systematic differences between Calypso and ultrasound for prostate localization.
- Published
- 2010
47. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer
- Author
-
Wang, Chenyang, King, Christopher R., Kamrava, Mitchell, Iwamoto, Keisuke S., Chen, Allen M., Low, Daniel, Kupelian, Patrick A., and Steinberg, Michael L.
- Published
- 2017
- Full Text
- View/download PDF
48. Location Matters: Stage I Non–Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes
- Author
-
Shaverdian, Narek, Veruttipong, Darlene, Wang, Jason, Kupelian, Patrick, Steinberg, Michael, and Lee, Percy
- Published
- 2017
- Full Text
- View/download PDF
49. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer
- Author
-
Shaverdian, Narek, Verruttipong, Darlene, Wang, Pin-Chieh, Kishan, Amar U., Demanes, D. Jeffrey, McCloskey, Susan, Kupelian, Patrick, Steinberg, Michael L., and King, Christopher R.
- Published
- 2017
- Full Text
- View/download PDF
50. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer
- Author
-
Ilg, Annette M., Laviana, Aaron A., Kamrava, Mitchell, Veruttipong, Darlene, Steinberg, Michael, Park, Sang-June, Burke, Michael A., Niedzwiecki, Douglas, Kupelian, Patrick A., and Saigal, Christopher
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.